Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407030 · ClinicalTrials.gov registry record · Phase 3
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia
A Phase 3 study of Cervical Dystonia, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
- 1
- Study location
NCT00407030 is a Phase 3 study of Cervical Dystonia that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 233 participants, above the 72-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (224% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00407030, a Phase 3 study of Cervical Dystonia, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
- 1
- Study location
Study Summary
At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG incobotulinumtoxinA (Xeomin) (240 Units)
- DRUG incobotulinumtoxinA (Xeomin) (120 Units)
Study Locations (1)
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407030
The ClinicalTrials.gov registry entry for NCT00407030 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (224% higher). The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Dystonia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00407030 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00407030 about?
NCT00407030 is a clinical study titled "IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia". At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.
What is the current status of trial NCT00407030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2006-07. Estimated completion is 2009-06.
What conditions does trial NCT00407030 study?
This clinical trial studies the following conditions: Cervical Dystonia.
What interventions are being tested in trial NCT00407030?
The interventions under investigation include: Placebo (DRUG), incobotulinumtoxinA (Xeomin) (240 Units) (DRUG), incobotulinumtoxinA (Xeomin) (120 Units) (DRUG).
Who is sponsoring clinical trial NCT00407030?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00407030 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Dystonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
COMPLETED · Phase 3
-
Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
COMPLETED · Phase 3
-
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
RECRUITING · Phase 2
-
Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia
RECRUITING · Phase 2
-
Effect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical Dystonia
RECRUITING · NA
-
Zinc as an Adjunctive Therapy for Cervical Dystonia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.